Skytrofa
Skytrofa ingredients
| Active ingredient | Strength |
|---|---|
| Lonapegsomatropin | 5.2 mg/1, 1.4 mg/1, 6.3 mg/1, .7 mg/1, 3.6 mg/1, 2.5 mg/1 |
What Skytrofa is used for
The FDA lists the approved uses on the official label (below). In the EU, lonapegsomatropin is approved as Skytrofa (previously Lonapegsomatropin Ascendis Pharma) for:
Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD])
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Skytrofa
- Generic name
- Lonapegsomatropin-tcgd
- Made by
- Ascendis Pharma Endocrinology, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Subcutaneous
- Drug class
- Recombinant Human Growth Hormone
- FDA approval
- Biologic licence (BLA) BLA761177
- On the US market since
- 2021
Official information
- MedlinePlus drug information (search for Lonapegsomatropin-tcgd)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Skytrofa?
Skytrofa (Lonapegsomatropin-tcgd) is a specialist medicine made by Ascendis Pharma Endocrinology, Inc., approved by the US FDA.
What are the ingredients of Skytrofa?
Skytrofa contains Lonapegsomatropin (5.2 mg/1, 1.4 mg/1, 6.3 mg/1, .7 mg/1, 3.6 mg/1, 2.5 mg/1).
Is Skytrofa approved in Europe?
The same active substance is approved in the EU as Skytrofa (previously Lonapegsomatropin Ascendis Pharma).
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA